Celldex Therapeutics Announces Upcoming Presentation at the Deutsche Bank 2012 dbAccess BioFEST

Celldex Therapeutics Announces Upcoming Presentation at the Deutsche Bank 2012 dbAccess BioFEST

<0> Celldex Therapeutics, Inc.Sarah Cavanaugh, 781-433-3161Vice President of IR & Corp CommorBMC CommunicationsBrad Miles, 646-513-3125 </0>

(NASDAQ: CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, is scheduled to present at the Deutsche Bank 2012 dbAccess BioFEST on Monday, December 3, 2012 at 2:50 pm ET at the Four Seasons Hotel in Boston, MA.

A of the presentation will be available online on the “Events & Presentations” page of the “Investors & Media” section of the Celldex website. A replay of the presentation will be available for 30 days following the event.

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit .

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.